Developing safer solutions for nuclease-free epigenetic editing

nAAVigen’s vector-based solutions provide a safer delivery system for epigenetic editing and potentially more accessible treatment for diseases like β-thalassemia and sickle cell disease.

Advancing vector-based editing treatments for genetic diseases

Our Platform

Epigenetic editing platform designed for increased safety and accessibility.

nAAVigen’s novel, proprietary vector-based approach enables epigenetic editing without introducing single or double strand breaks in the DNA – a “nuclease-free” solution for safer epigenetic editing.

Learn More

β-thalassemia and sickle cell disease

The most common genetic diseases

β-thalassemia and sickle cell disease

1 out of 600 people

β-thalassemia and sickle cell disease affect 1 out of 600 people, together the most common genetic diseases. While current treatments offer hope for curing these life-threatening diseases, an intensive gene editing process – outside the body followed by hematopoietic stem cell transplantation – coupled with long-term safety concerns, significantly limits therapeutic use.

Developing safer solutions for nuclease-free epigenetic editing

Advancing vector-based editing treatments for genetic diseases

Epigenetic editing platform designed for increased safety and accessibility. nAAVigen’s novel, proprietary vector-based approach enables epigenetic editing without introducing single or double strand breaks in the DNA – a “nuclease-free” solution for safer epigenetic editing.

β-thalassemia and sickle cell disease

β-thalassemia and sickle cell disease

Epigenetic editing platform designed for increased safety and accessibility.

nAAVigen’s novel, proprietary vector-based approach enables epigenetic editing without introducing single or double strand breaks in the DNA – a “nuclease-free” solution for safer epigenetic editing.